We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
OTSUKA PHARMACEUTICAL EUROPE LTD WITHDRAWS ITS APPLICATION FOR AN EXTENSION OF INDICATION FOR ABILIFY (ARIPIPRAZOLE).
- Abstract
The article reports on the move of Otsuka Pharmaceutical Europe Ltd. to formally notify the decision of the European Medicines Agency to withdraw its application for an extension of indication for the authorization of the Abilify tablets, orodispersible tablets and oral solution. It notes that Abilify was first authorized in June 4, 2004 in the European Union. It is currently indicated for treating patients with schizophrenia as well as prevent manic episodes of bipolar I disorder.
- Subjects
DRUG administration; DRUG tablets; SCHIZOPHRENIA treatment; PEOPLE with schizophrenia; OTSUKA Pharmaceutical Europe Ltd.; EUROPEAN Medicines Agency; EUROPEAN Union; MEDICAL care
- Publication
Psychiatry (1550-5952), 2009, Vol 6, Issue 11, p9
- ISSN
1550-5952
- Publication type
Article